Table 3.
Univariate and multivariate analysis of different risk factors for organ-specific toxicities.
| Toxicity | Variable | Comparison | Univariate Analysis | Multivariate Analysis | Multivariate Analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Step One | Step Two | ||||||||||
| RR | Range | p | RR | Range | p | RR | Range | p | |||
| Disease | ALL vs. AML | 0.71 | 0.34–1.50 | 0.371 | |||||||
| MDS vs. AML | 1.46 | 0.45–4.77 | 0.533 | ||||||||
| Cardiac | TBI dose | 12 Gy vs. 8 Gy | 0.73 | 0.36–1.47 | 0.373 | ||||||
| Sex | male vs. female | 1.32 | 0.72–2.41 | 0.378 | |||||||
| Age at SCT | 1.03 | 1.00–1.05 | 0.048 | ||||||||
| Disease | ALL vs. AML | 1.04 | 0.63–1.71 | 0.886 | |||||||
| MDS vs. AML | 0.81 | 0.25–2.61 | 0.729 | ||||||||
| TBI dose | 12 Gy vs. 8 Gy | 0.75 | 0.44–1.29 | 0.301 | |||||||
| Pulmonary | Conditioning | flu vs. cy | 1.79 | 0.98–3.30 | 0.060 | ||||||
| chemotherapy | |||||||||||
| Sex | male vs. female | 0.90 | 0.57–1.42 | 0.641 | |||||||
| Age at SCT | 1.01 | 1.00–1.03 | 0.139 | ||||||||
| Disease | ALL vs. AML | 0.25 | 0.11–0.56 | 0.001 | 0.32 | 0.13–0.78 | 0.012 | 0.31 | 0.13–0.74 | 0.008 | |
| MDS vs. AML | 1.07 | 0.33–3.50 | 0.910 | 0.99 | 0.30–3.32 | 0.991 | 1.00 | 0.30–3.34 | 0.997 | ||
| Renal | TBI dose | 12 Gy vs. 8 Gy | 0.29 | 0.13–0.67 | 0.004 | 0.90 | 0.35–2.33 | 0.826 | |||
| Sex | male vs. female | 0.94 | 0.55–1.63 | 0.836 | |||||||
| Age at SCT | 1.06 | 1.03–1.09 | <0.001 | 1.06 | 1.03–1.09 | <0.001 | 1.06 | 1.03–1.09 | <0.001 | ||
| Disease | ALL vs. AML | 1.23 | 0.70–2.17 | 0.471 | |||||||
| MDS vs. AML | 1.25 | 0.38–4.10 | 0.713 | ||||||||
| Neurological | TBI dose | 12 Gy vs. 8 Gy | 0.94 | 0.81–1.10 | 0.436 | ||||||
| Sex | male vs. female | 0.63 | 0.37–1.07 | 0.089 | |||||||
| Age at SCT | 1.02 | 1.00–1.04 | 0.147 | ||||||||
| Disease | ALL vs. AML | 1.27 | 0.72–2.23 | 0.417 | |||||||
| MDS vs. AML | 1.77 | 0.58–5.42 | 0.320 | ||||||||
| TBI dose | 12 Gy vs. 8 Gy | 2.45 | 1.41–4.26 | 0.002 | 2.29 | 1.22–4.30 | 0.010 | 2.60 | 1.49–4.54 | 0.001 | |
| Ocular | Sex | male vs. female | 1.33 | 0.79–2.26 | 0.285 | ||||||
| Age at SCT | 1.00 | 0.99–1.02 | 0.689 | ||||||||
| Previous cranial | yes vs. no | 2.12 | 1.12–4.00 | 0.020 | 1.38 | 0.67–2.85 | 0.387 | ||||
| irradiation | |||||||||||
| Disease | ALL vs. AML | 0.90 | 0.28–2.92 | 0.865 | |||||||
| Secondary | MDS vs. AML | 3.28 | 0.70–15.33 | 0.130 | |||||||
| neoplasia | TBI dose | 12 Gy vs. 8 Gy | 0.44 | 0.14–1.42 | 0.168 | ||||||
| Sex | male vs. female | 1.80 | 0.62–5.21 | 0.278 | |||||||
| Age at SCT | 1.04 | 1.00–1.08 | 0.078 | ||||||||
ALL: acute lymphoid leukemia, AML: acute myeloid leukemia, cy: cyclophosphamide, flu: fludarabine, Gy: Gray, MDS: myelodysplastic syndrome, RR: relative risk, SCT: stem cell transplantation, TBI: total body irradiation.